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Erlotinib is accepted as a standard second-line chemotherapeutic agent in patients 
with non-small cell lung cancer who are refractory or resistant to first-line plati-
num-based chemotherapy. There has been no previous report of bowel perforation 
with or without gastrointestinal metastases related to erlotinib in patients with non-
small cell lung cancer. The exact mechanism of bowel perforation in patients who 
received erlotinib remains unclear. In this report, we report the first case of entero-
cutaneous fistula in a female patient with metastatic non-small cell lung cancer 9 
months, following medication with erlotinib as second-line chemotherapy.  
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INTRODUCTION
Chemotherapy is a mainstay treatment for advanced or metastatic non-small cell 
lung cancer (NSCLC).1 Erlotinib, an epidermal growth factor receptor-tyrosine ki-
nase inhibitor (EGFR-TKI), has been shown to be effective for Asian patients with 
favorable clinical features, such as female gender, never or non-smoker, and ade-
nocarcinoma.2 The most common adverse effect is skin rash. However, other ad-
verse effects are relatively minor and manageable.2-6
Among several targeted agents with different mechanisms of action, patients 
treated with vascular endothelial growth factor (VEGF)-targeted agents, such as be-
vacizumab, develop hypertension, thrombosis, gastrointestinal bleeding, and bowel 
perforation as uncommon adverse effects.7-11 However, there has been no previous 
report of gastrointestinal perforation or fistula related to erlotinib administration.
Here, we report a case of enterocutaneous fistula in a patient with NSCLC after 
the ninth course of erlotinib treatment as a second-line palliative chemotherapy.
CASE REPORT
A 66-year-old female was diagnosed with metastatic non-small cell adenocarcino-
ma of the lung [NSCLC; cT4N0M1 for metastases of the lung to the contralateral Yun-Hong Cheon, et al.
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of bone metastasis was detected in the bone biopsy speci-
men, which was compatible with a benign compression frac-
ture related to severe osteoporosis. Additionally, ibuprofen 
(200 mg three times daily) was added to relieve low back 
pain for 7 days after the procedures.
Nine months after starting second-line chemotherapy with 
erlotinib, the patient was admitted with purulent yellowish 
sputum, cough, and mild shortness of breath without abdom-
inal symptoms. Chest CT scan demonstrated decreased size 
of the primary lung mass, which was still evaluated as a par-
tial response, with focal, patchy consolidation and peribron-
chial thickening in the left lung field, clinically compatible 
with pneumonia. 
On physical examination, a coarse breathing sound with 
a crackle, especially in the left lung field, was detected, and 
an enterocutaneous fistula with leakage of fecal material 
was found in the previous sigmoid colon herniation through 
the abdominal wall defect (Fig. 1A and B). Nevertheless, 
no sign of strangulation, including tenderness or rebound 
tenderness, was observed. Fistulography also demonstrated 
passage of contrast media into the sigmoid colon without 
another fistula (Fig. 2). Further administration of erlotinib 
was withheld after documentation of the enterocutaneous 
fistula. 
After resolution of pneumonia via empirical antibiotic 
treatment for 14 days, a scheduled sigmoid colon resection 
and primary anastomosis were performed at the Depart-
ment of General Surgery. Surgical pathologic findings in-
cluded submucosal edema and serosal hemorrhage of the 
perforated sigmoid colon, consistent with enterocutaneous 
fistula and no metastatic tumor foci in the sigmoid colon 
(Fig. 3A and B). Ten days postoperatively, the patient was 
discharged with complete recovery from the enterocutane-
ous fistula. She was alive and well on regular follow-up at 
lung and pleura on 18F-fluorodeoxyglucose positron emis-
sion tomography computed tomography (FDG-PET CT) 
scan] in January 2008. The patient had a history of explor-
atory laparotomy and a total hysterectomy, due to acute ab-
domen about 30 years earlier. Physical examination re-
vealed sigmoid colon herniation through an abdominal wall 
defect, with no sign or symptom of strangulation. Although 
surgical management of the herniated colon loop and clo-
sure of the abdominal wall were strongly recommended, 
she refused further surgical treatment, because there had 
been no symptom, such as abdominal pain or bowel habit 
abnormality associated with the sigmoid colon herniation, 
over the previous 30 years.
She was treated with a first-line chemotherapy, including 
cisplatin (70 mg/m2, day 1) and docetaxel (70 mg/m2, day 
1) every 3 weeks for 6 cycles from January 2008 to July 
2008. Following completion of 6 cycles of first-line chemo-
therapy, a chest CT scan showed a partial response, accord-
ing to the Response Evaluation Criteria in Solid Tumors 
(RECIST).
In October 2008, second-line chemotherapy with erlo-
tinib was started because a follow-up chest CT scan re-
vealed regrowth of the primary lung mass in the left upper 
lobe and increased malignant pleural effusion. A subse-
quent chest CT scan showed persistent partial response at 
the first, third, fifth, and seventh month following erlotinib 
administration.
In November 2008 (seventh month following erlotinib 
administration), the patient complained of low back pain 
after a fall at home, and a compression fracture of the fifth 
lumbar vertebra was detected on a simple spine X-ray and 
spine magnetic resonance image (MRI). Percutaneous ver-
tebroplasty and concomitant bone biopsy were performed 
at the Department of Neurosurgery. However, no evidence 
Fig. 2. Fistulography shows well passage of contrast media into the sigmoid 
colon without another fistu.
Fig. 1. (A and B) White arrow indicates an enterocutaneous fistula in the 
sigmoid colon herniation through the abdominal wall defect.
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to bowel perforation regardless of their mechanism of ac-
tion, especially in patients with visceral metastases caused 
by tumor regression and necrosis, our patient showed no ev-
idence of bowel metastasis, according to radiologic findings 
at initial diagnosis or during administration of erlotinib, or 
pathologic findings of the post-operative resected bowel 
specimen.
In conclusion, physicians should be aware of the rare, but 
possible, adverse effect of bowel perforation or fistula fol-
lowing administration of erlotinib, even in NSCLC patients 
without visceral metastases, and erlotinib administration 
should be discontinued when patients develop gastrointesti-
nal perforation.
REFERENCES
1. Non-Small Cell Lung Cancer Collaborative Group. Chemothera-
py and supportive care versus supportive care alone for advanced 
non-small cell lung cancer. Cochrane Database Syst Rev 2010: 
CD007309. 
2. Uhm JE, Park BB, Ahn MJ, Lee J, Ahn JS, Kim SW, et al. Erlotinib 
monotherapy for stage IIIB/IV non-small cell lung cancer: a mul-
ticenter trial by the Korean Cancer Study Group. J Thorac Oncol 
2009;4:1136-43. 
3. Dudek AZ, Kmak KL, Koopmeiners J, Keshtgarpour M. Skin 
rash and bronchoalveolar histology correlates with clinical benefit 
in patients treated with gefitinib as a therapy for previously treated 
advanced or metastatic non-small cell lung cancer. Lung Cancer 
2006;51:89-96. 
4. Mohamed MK, Ramalingam S, Lin Y, Gooding W, Belani CP. 
Skin rash and good performance status predict improved survival 
with gefitinib in patients with advanced non-small cell lung can-
cer. Ann Oncol 2005;16:780-5. 
5. Hotta K, Kiura K, Ueoka H, Tabata M, Fujiwara K, Kozuki T, et 
al. Effect of gefitinib (‘Iressa’, ZD1839) on brain metastases in 
patients with advanced non-small-cell lung cancer. Lung Cancer 
2004;46:255-61. 
6. Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, 
et al. Efficacy of gefitinib, an inhibitor of the epidermal growth fac-
tor receptor tyrosine kinase, in symptomatic patients with non-small 
cell lung cancer: a randomized trial. JAMA 2003;290:2149-58. 
7. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh 
V, et al. Phase III trial of cisplatin plus gemcitabine with either 
placebo or bevacizumab as first-line therapy for nonsquamous 
non-small-cell lung cancer: AVAil. J Clin Oncol 2009;27:1227-34. 
8. Di Costanzo F, Mazzoni F, Micol Mela M, Antonuzzo L, Chec-
cacci D, Saggese M, et al. Bevacizumab in non-small cell lung 
cancer. Drugs 2008;68:737-46. 
9. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemun-
aitis JJ, Jablons DM, et al. Randomized phase II trial comparing 
bevacizumab plus carboplatin and paclitaxel with carboplatin and 
paclitaxel alone in previously untreated locally advanced or meta-
static non-small-cell lung cancer. J Clin Oncol 2004;22:2184-91. 
10. Cohen MH, Gootenberg J, Keegan P, Pazdur R. FDA drug ap-
proval summary: bevacizumab plus FOLFOX4 as second-line 
the outpatient clinic, with no evidence of lung cancer pro-
gression.
DISCUSSION
To our knowledge, there is no previously reported case of 
enterocutaneous fistula without intestinal metastasis in a pa-
tient with NSCLC who received erlotinib. 
Hoffman-La Roche Ltd. announced that gastrointestinal 
perforation (including fatalities) has been reported in pa-
tients receiving erlotinib, and the prescribing information in-
dicates that patients receiving concomitant anti-angiogenic 
agents, corticosteroids, nonsteroidal anti-inflammatory drugs 
(NSAIDs), and/or taxane-based chemotherapy, or who have 
a prior history of peptic ulceration or diverticular disease, 
are at increased risk of gastrointestinal perforation.12
Our patient had risk factors related to gastrointestinal per-
foration during medication with erlotinib. First, she had a 
history of previous abdominal surgery, which was eventual-
ly complicated with sigmoid colon herniation through an 
abdominal wall defect. This condition may cause a continu-
ous increase of the pressure on already weakened areas of 
the bowel, thus further predisposing patients to bowel perfo-
rations or fistulae that re-epithelialize poorly during erlotinib 
administration.13,14 Second, NSAIDs were administered con-
comitantly for 7 days following percutaneous vertebroplasty, 
which could block COX 1 and COX 2 enzyme activity, 
also leading to gastrointestinal perforations through the de-
velopment of ulcers and poor ulcer healing.13,14 There is 
strong evidence that HER-1/EGFR and VEGF share a com-
mon downstream signaling pathway both in vitro and in vivo, 
and they exert effects on tumor cells directly or indirectly.15-18 
Although we suggest that potent cytotoxic agents can lead 
Fig. 3. (A and B) Submucosal edema and serosal hemorrhage of the perfo-
rated sigmoid colon.
A BYun-Hong Cheon, et al.
Yonsei Med J   http://www.eymj.org   Volume 52   Number 4   July 2011 698
drogen-independent human prostate cancer growing in the bone of 
nude mice. Clin Cancer Res 2003;9:1200-10. 
16. de Jong JS, van Diest PJ, van der Valk P, Baak JP. Expression of 
growth factors, growth-inhibiting factors, and their receptors in in-
vasive breast cancer. II: Correlations with proliferation and angio-
genesis. J Pathol 1998;184:53-7. 
17. Petit AM, Rak J, Hung MC, Rockwell P, Goldstein N, Fendly B, 
et al. Neutralizing antibodies against epidermal growth factor and 
ErbB-2/neu receptor tyrosine kinases down-regulate vascular en-
dothelial growth factor production by tumor cells in vitro and in 
vivo: angiogenic implications for signal transduction therapy of 
solid tumors. Am J Pathol 1997;151:1523-30. 
18. Bruns CJ, Harbison MT, Davis DW, Portera CA, Tsan R, McCon-
key DJ, et al. Epidermal growth factor receptor blockade with 
C225 plus gemcitabine results in regression of human pancreatic 
carcinoma growing orthotopically in nude mice by antiangiogenic 
mechanisms. Clin Cancer Res 2000;6:1936-48. 
treatment of colorectal cancer. Oncologist 2007;12:356-61. 
11. Saif MW, Elfiky A, Salem RR. Gastrointestinal perforation due to 
bevacizumab in colorectal cancer. Ann Surg Oncol 2007;14:1860-9. 
12. Johnson JR, Cohen M, Sridhara R, Chen YF, Williams GM, Duan 
J, et al. Approval summary for erlotinib for treatment of patients 
with locally advanced or metastatic non-small cell lung cancer af-
ter failure of at least one prior chemotherapy regimen. Clin Cancer 
Res 2005;11:6414-21. 
13. Schellhaas E, Loddenkemper C, Schmittel A, Buhr HJ, Pohlen U. 
Bowel perforation in non-small cell lung cancer after bevacizum-
ab therapy. Invest New Drugs 2009;27:184-7. 
14. Badgwell BD, Camp ER, Feig B, Wolff RA, Eng C, Ellis LM, et al. 
Management of bevacizumab-associated bowel perforation: a case 
series and review of the literature. Ann Oncol 2008;19:577-82. 
15. Kim SJ, Uehara H, Karashima T, Shepherd DL, Killion JJ, Fidler 
IJ. Blockade of epidermal growth factor receptor signaling in tu-
mor cells and tumor-associated endothelial cells for therapy of an-